Xencor. has filed a patent for novel heterodimeric proteins, including heterodimeric antibodies. The patent claim has been canceled. GlobalData’s report on Xencor gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Novel heterodimeric proteins or heterodimeric antibodies
A recently filed patent (Publication Number: US20230279154A1) describes a heterodimeric antibody and methods for its production. The patent claims cover various aspects of the antibody, including its composition, nucleic acid sequences encoding it, expression vector compositions, host cells, and methods of manufacturing.
The heterodimeric antibody described in the patent consists of two monomers. The first monomer includes a variant human IgG1 Fc domain with specific amino acid substitutions and a single chain Fv (scFv) region that binds to a specific antigen. The second monomer includes a variant human IgG1 Fc domain with a different amino acid substitution and a variable heavy chain. The light chain of the antibody consists of a variable light chain and a constant light chain. The Fc domains of the first and/or second monomer may also have additional amino acid substitutions.
The patent also covers the nucleic acid compositions encoding the first monomer, second monomer, and light chain of the heterodimeric antibody. These nucleic acid compositions can be used to produce the antibody through recombinant DNA technology. The patent further describes expression vector compositions, which are used to introduce the nucleic acid sequences into host cells for expression.
The host cells containing the expression vector compositions are also claimed in the patent. These host cells are cultured under specific conditions to allow the expression of the heterodimeric antibody. The antibody can then be recovered from the host cells.
In addition to the heterodimeric antibody described above, the patent also covers similar antibodies with variant human IgG2 Fc domains or variant human IgG4 Fc domains. These antibodies have similar compositions and can be produced using the same methods described in the patent.
Overall, the patent provides a detailed description of a heterodimeric antibody and its production methods. The claims cover various aspects of the antibody, including its composition, nucleic acid sequences, expression vectors, host cells, and manufacturing processes. This patent could have significant implications for the development of therapeutic antibodies with improved properties.
To know more about GlobalData’s detailed insights on Xencor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
